8-K current report · filed Aug 13, 2026

Lucid Diagnostics Inc. (LUCD) 8-K Current Report: August 13, 2026

Item 2.02Item EX-99.1Item 7.01LUCD overview

Short answer

Lucid Diagnostics Inc. (LUCD) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Fiscal quarter ended June 30, 2026 results and business update announced.

Lucid Diagnostics Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal quarter ended June 30, 2026 results and business update announced
  • Press release contains the substantive financial figures and operating commentary
  • Exhibit 99.1 is the key investor document for assessing performance and outlook

Item 7.01 · Regulation FD Disclosure

  • Item 7.01 incorporates Item 2.02 disclosure by reference
  • Investor-relevant information appears in the company’s earnings release or report under Item 2.02

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $1.474 million, up from $1.163 million, with 2,770 EsoGuard tests processed
  • Concert secured first laboratory benefit manager coverage policy, with multiple client health plans adopting it
  • GAAP net loss attributable to common stockholders $14.715 million, including $3.028 million preferred-stock dividends
  • Cash $33.4 million at June 30, 2026, versus $34.7 million at December 31, 2025
  • Non-GAAP adjusted loss $10.854 million, or $0.06 per share, highlighting continued funding needs despite commercial progress

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Lucid Diagnostics Inc. 8-K filings

Get the next LUCD 8-K as it lands

Follow LUCD for push alerts, or ask the research agent what this filing means.